COVID-19 related ICU admissions in paediatric and young adult patients in Australia: a national case series 2020–2022

Otto, Madeleine; Britton, Philip N; Neto, Ary Serpa; Erickson, Simon; Festa, Marino S.; Crawford, Nigel; Burrell, Aidan; Udy, Andrew

doi:10.1016/j.lanwpc.2023.100763

Cited by 2 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Countries have lifted most or all public health and social measures following significant reduction in rates of hospitalisation, admission to intensive care units and deaths across all age groups. 28 29 While this health indicators clearly mark the end to a global emergency, the virus continues to spread and evolve and COVID-19 remains a threat, especially to older persons and adults with underlying health conditions. WHO has recently released a ‘Roadmap on uses of COVID-19 vaccines in the context of Omicron and high population immunity’ 30 which assumes that the virus will continue to evolve but cause less severe disease with possible surge in infections that will require booster doses to maintain protection in the high priority groups.…”

Section: Introductionmentioning

confidence: 99%

Priority populations’ experiences of isolation, quarantine and distancing for COVID-19: protocol for a longitudinal cohort study (Optimise Study)

Pedrana,

Bowring,

Heath

et al. 2024

BMJ Open

View full text Add to dashboard Cite

IntroductionLongitudinal studies can provide timely and accurate information to evaluate and inform COVID-19 control and mitigation strategies and future pandemic preparedness. The Optimise Study is a multidisciplinary research platform established in the Australian state of Victoria in September 2020 to collect epidemiological, social, psychological and behavioural data from priority populations. It aims to understand changing public attitudes, behaviours and experiences of COVID-19 and inform epidemic modelling and support responsive government policy.Methods and analysisThis protocol paper describes the data collection procedures for the Optimise Study, an ongoing longitudinal cohort of ~1000 Victorian adults and their social networks. Participants are recruited using snowball sampling with a set of seeds and two waves of snowball recruitment. Seeds are purposively selected from priority groups, including recent COVID-19 cases and close contacts and people at heightened risk of infection and/or adverse outcomes of COVID-19 infection and/or public health measures. Participants complete a schedule of monthly quantitative surveys and daily diaries for up to 24 months, plus additional surveys annually for up to 48 months. Cohort participants are recruited for qualitative interviews at key time points to enable in-depth exploration of people’s lived experiences. Separately, community representatives are invited to participate in community engagement groups, which review and interpret research findings to inform policy and practice recommendations.Ethics and disseminationThe Optimise longitudinal cohort and qualitative interviews are approved by the Alfred Hospital Human Research Ethics Committee (# 333/20). The Optimise Study CEG is approved by the La Trobe University Human Ethics Committee (# HEC20532). All participants provide informed verbal consent to enter the cohort, with additional consent provided prior to any of the sub studies. Study findings will be disseminated through public website (https://optimisecovid.com.au/study-findings/) and through peer-reviewed publications.Trial registration numberNCT05323799.

show abstract

Section: Introductionmentioning

confidence: 99%

Priority populations’ experiences of isolation, quarantine and distancing for COVID-19: protocol for a longitudinal cohort study (Optimise Study)

Pedrana,

Bowring,

Heath

et al. 2024

BMJ Open

View full text Add to dashboard Cite

show abstract

The seroprevalence of SARS-CoV-2-specific antibodies in Australian children: a cross sectional study

Koirala,

McRae,

Britton

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Following reduction of public health and social measures concurrent with SARS-CoV-2 Omicron emergence in late 2021 in Australia, COVID-19 case notification rates rose rapidly. As rates of direct viral testing and reporting dropped, true infection rates were most likely to be underestimated. Objective: To better understand infection rates and immunity in this population, we aimed to estimate SARS-CoV-2 seroprevalence in Australians aged 0-19 years. Methods: We conducted a national cross sectional serosurvey from June 1, 2022, to August 31, 2022, in children aged 0-19 years undergoing an anesthetic procedure at eight tertiary pediatric hospitals. Participant questionnaires were administered, and blood samples tested using the Roche Elecsys Anti-SARS-CoV-2 total spike and nucleocapsid antibody assays. S and N seroprevalence adjusted for geographic and socioeconomic imbalances in the participant sample compared to the Australian population was estimated using multilevel regression and poststratification within a Bayesian framework. Results: Blood was collected from 2,046 participants (median age: 6.6 years). Adjusted seroprevalence of spike-antibody was 92.1 % (95% credible interval (CrI) 91.0-93.3%) and nucleocapsid-antibody was 67.0% (95% CrI 64.6-69.3). In unvaccinated children spike and nucleocapsid antibody seroprevalences were 84.2% (95% CrI 81.9-86.5) and 67.1% (95%CrI 64.0-69.8), respectively. Seroprevalence increased with age but was similar across geographic distribution and socioeconomic quintiles. Conclusion: Most Australian children and adolescents aged 0-19 years, across all jurisdictions were infected with SARS-CoV-2 by August 2022, suggesting rapid and uniform spread across the population in a very short time period. High seropositivity in unvaccinated children informed COVID-19 vaccine recommendations in Australia. Funding: Australian Government Department of Health and Aged Care.

show abstract

COVID-19 related ICU admissions in paediatric and young adult patients in Australia: a national case series 2020–2022

Cited by 2 publications

References 40 publications

Priority populations’ experiences of isolation, quarantine and distancing for COVID-19: protocol for a longitudinal cohort study (Optimise Study)

Priority populations’ experiences of isolation, quarantine and distancing for COVID-19: protocol for a longitudinal cohort study (Optimise Study)

The seroprevalence of SARS-CoV-2-specific antibodies in Australian children: a cross sectional study

Contact Info

Product

Resources

About